The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity-Reference-Cited by-同舟云学术

The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity

Published:2016-08-09 Issue:10 Volume:65 Page:1169-1175
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Abuhay Mastewal,Kato Jason,Tuscano Emily,Barisone Gustavo A.,Sidhu Ranjit S.,O’Donnell Robert T.,Tuscano Joseph M.^ORCID

Funder

Schwedler Family Foundation

deLeuze Non-toxic Cure for Lymphoma Endowment Fund

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-016-1873-y.pdf

Reference26 articles.

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29. doi: 10.3322/caac.21208

2. SEER Cancer Statistics Review (2007) 1975–2004, based on November 2006 SEER data submission, posted to the SEER web site, 2007. In: Ries LAG MD, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (ed). National Cancer Institute, Bethesda

3. Kato J, O’Donnell RT, Abuhay M, Tuscano JM (2012) Efficacy and toxicity of a CD22-targeted antibody–saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma. Oncoimmunology 1:1469–1475. doi: 10.4161/onci.21815

4. Tedder TF, Poe JC, Haas KM (2005) CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88:1–50. doi: 10.1016/S0065-2776(05)88001-0

5. Shan D, Press OW (1995) Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 154:4466–4475

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy;Cancers;2024-01-10

2. Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin;Molecular Cancer Therapeutics;2022-08-05

3. Siglec and anti-Siglec therapies;Current Opinion in Chemical Biology;2021-06

4. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies;Current Hematologic Malignancy Reports;2018-10-25

5. A developed antibody–drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line;Artificial Cells, Nanomedicine, and Biotechnology;2018-03-09